- Home
- AMZN vs JNJ Comparison
AMZN vs JNJ Comparison
Compare AMZN & JNJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMZN | JNJ |
|---|---|---|
| Founded | 1994 | 1886 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8T | 542.4B |
| IPO Year | 1997 | 2003 |
Fundamental Metrics
Financial Performance| Metric | AMZN | JNJ |
|---|---|---|
| Price | $248.13 | $263.97 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 60 | 23 |
| Target Price | ★ $331.46 | $279.41 |
| AVG Volume (30 Days) | ★ 25.1M | 6.6M |
| Earning Date | 10-29-2026 | 10-13-2026 |
| Dividend Yield | N/A | ★ 2.00% |
| EPS Growth | 29.66 | ★ 90.50 |
| EPS | ★ 8.53 | 4.49 |
| Revenue | ★ $716,924,000,000.00 | N/A |
| Revenue This Year | $15.57 | $7.46 |
| Revenue Next Year | $14.57 | $6.60 |
| P/E Ratio | ★ $29.30 | $59.73 |
| Revenue Growth | ★ 12.38 | N/A |
| 52 Week Low | $196.00 | $184.66 |
| 52 Week High | $287.20 | $281.07 |
Technical Indicators
Market Signals| Indicator | AMZN | JNJ |
|---|---|---|
| Relative Strength Index (RSI) | 43.18 | 53.03 |
| Support Level | $245.71 | $262.26 |
| Resistance Level | $250.15 | $266.91 |
| Average True Range (ATR) | 6.24 | 5.81 |
| MACD | -0.42 | 1.14 |
| Stochastic Oscillator | 7.56 | 76.08 |
Price Performance
Historical ComparisonAbout AMZN Amazon.com Inc.
Amazon is the leading online retailer and marketplace for third party sellers. Retail related revenue represents approximately 74% of total, followed by Amazon Web Services (17%), and advertising services (9%). International segments constitute 22% of Amazon's total revenue, led by Germany, the United Kingdom, and Japan.
About JNJ Johnson & Johnson
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.